CEP290 and Leber congenital amaurosis: PE inclusions due to deep-intronic variants are attractive targets for antisense oligonucleotide (AON)-based splicing correction.23 In the field of IRDs, these molecules have shown therapeutic potential for deep-intronic pathogenic variants in CEP290,24–27USH2A,28 or OPA1,29 and a phase 1/2 clinical trial using AONs to treat CEP290-associated Leber congenital amaurosis is ongoing (NCT03140969).